JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
US4323581A
(en)
|
1978-07-31 |
1982-04-06 |
Johnson & Johnson |
Method of treating carcinogenesis
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US4923986A
(en)
|
1987-03-09 |
1990-05-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Derivatives of physiologically active substance K-252
|
US4904768A
(en)
|
1987-08-04 |
1990-02-27 |
Bristol-Myers Company |
Epipodophyllotoxin glucoside 4'-phosphate derivatives
|
JP2766360B2
(ja)
|
1988-02-04 |
1998-06-18 |
協和醗酵工業株式会社 |
スタウロスポリン誘導体
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
EP0540185A1
(en)
|
1991-10-10 |
1993-05-05 |
Schering Corporation |
4'-(N-substituted-N-oxide)staurosporine derivatives
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
AU3064992A
(en)
|
1991-11-08 |
1993-06-07 |
University Of Southern California |
Compositions containing k-252 compounds for potentiation of neurotrophin activity
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5948898A
(en)
|
1992-03-16 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US5756494A
(en)
|
1992-07-24 |
1998-05-26 |
Cephalon, Inc. |
Protein kinase inhibitors for treatment of neurological disorders
|
US5621100A
(en)
|
1992-07-24 |
1997-04-15 |
Cephalon, Inc. |
K-252a derivatives for treatment of neurological disorders
|
ATE378406T1
(de)
|
1992-08-31 |
2007-11-15 |
Ludwig Inst Cancer Res |
Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
|
DE69331228T4
(de)
|
1992-09-21 |
2002-09-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Heilmittel für thrombozytopenia
|
EP1167384B1
(en)
|
1992-10-28 |
2006-12-13 |
Genentech, Inc. |
HVEGF Receptor as Vascular endothelial cell growth factor antagonists
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
KR100341341B1
(ko)
|
1993-07-15 |
2002-11-25 |
미네소타 마이닝 앤드 매뉴팩춰링 캄파니 |
이미다조[4,5-c]피리딘-4-아민
|
US5478932A
(en)
|
1993-12-02 |
1995-12-26 |
The Board Of Trustees Of The University Of Illinois |
Ecteinascidins
|
EP0817627B1
(en)
|
1993-12-23 |
2005-03-09 |
Eli Lilly And Company |
Protein kinase c inhibitors
|
US5587459A
(en)
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US6083903A
(en)
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
JP3088018B2
(ja)
|
1995-03-30 |
2000-09-18 |
ファイザー・インコーポレーテッド |
キナゾリン誘導体
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
AU6888196A
(en)
|
1995-08-11 |
1997-03-12 |
Yale University |
Glycosylated indolocarbazole synthesis
|
FR2741881B1
(fr)
|
1995-12-01 |
1999-07-30 |
Centre Nat Rech Scient |
Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
|
SI0865440T1
(en)
|
1995-12-08 |
2002-08-31 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
|
KR100447918B1
(ko)
|
1996-07-25 |
2005-09-28 |
동아제약주식회사 |
대장을포함한위장관보호작용을갖는플라본및플라바논화합물
|
IL128124A0
(en)
|
1996-08-02 |
1999-11-30 |
Genesense Technologies Inc |
Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6126965A
(en)
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
ATE311884T1
(de)
|
1997-07-12 |
2005-12-15 |
Cancer Rec Tech Ltd |
Cyclin-abhängige-kinase inhibierende purinderivate
|
US7348025B2
(en)
|
1997-09-23 |
2008-03-25 |
Research Development Foundation |
Small particle liposome aerosols for delivery of anticancer drugs
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
NZ508815A
(en)
|
1998-05-29 |
2005-02-25 |
Sugen Inc |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
US20030083242A1
(en)
|
1998-11-06 |
2003-05-01 |
Alphonse Galdes |
Methods and compositions for treating or preventing peripheral neuropathies
|
PT1189641E
(pt)
|
1999-06-25 |
2009-11-04 |
Genentech Inc |
Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2
|
US6806266B1
(en)
|
1999-07-13 |
2004-10-19 |
Kyowa Hakko Kogyo Co., Ltd. |
Staurosporin derivatives
|
EE05330B1
(et)
|
1999-11-05 |
2010-08-16 |
Astrazeneca Ab |
Kinasoliini derivaadid kui VEGF-i inhibiitorid
|
DE122010000004I1
(de)
|
2000-02-15 |
2010-04-15 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
DK1274718T3
(da)
|
2000-04-12 |
2007-02-12 |
Genaera Corp |
En fremgangsmåde til forberedelse af 7.alpha.-hydroxy 3-aminosubstituerede steroler vee en ubeskyttet 7.alpha.-hydroxy gruppe
|
DE60126611T2
(de)
|
2000-06-30 |
2007-11-22 |
Glaxo Group Ltd., Greenford |
Ditosylatsalze von chinazolinverbindungen
|
DK1317442T3
(da)
|
2000-09-11 |
2006-02-13 |
Chiron Corp |
Quinolinonderivater som tyrosinkinaseinhibitorer
|
US6677450B2
(en)
|
2000-10-06 |
2004-01-13 |
Bristol-Myers Squibb Company |
Topoisomerase inhibitors
|
EP1392859B1
(en)
|
2001-01-16 |
2006-05-10 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
WO2002062826A1
(fr)
|
2001-02-07 |
2002-08-15 |
Vadim Viktorovich Novikov |
Procede de fabrication des peptides
|
EP1404689A1
(en)
|
2001-07-02 |
2004-04-07 |
Debiopharm S.A. |
Oxaliplatin active substance with a very low content of oxalic acid
|
KR100484504B1
(ko)
|
2001-09-18 |
2005-04-20 |
학교법인 포항공과대학교 |
쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
|
US20030134846A1
(en)
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
US6927036B2
(en)
|
2002-02-19 |
2005-08-09 |
Xero Port, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
EP1499311B1
(en)
|
2002-03-29 |
2009-11-04 |
Novartis Vaccines and Diagnostics, Inc. |
Substituted benzazoles and use thereof as raf kinase inhibitors
|
US6900342B2
(en)
|
2002-05-10 |
2005-05-31 |
Dabur India Limited |
Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
|
US6727272B1
(en)
|
2002-07-15 |
2004-04-27 |
Unitech Pharmaceuticals, Inc. |
Leflunomide analogs for treating rheumatoid arthritis
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
EP1587473A4
(en)
|
2002-12-27 |
2008-08-13 |
Novartis Vaccines & Diagnostic |
THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
|
EP1594524B1
(en)
|
2003-01-21 |
2012-08-15 |
Novartis Vaccines and Diagnostics, Inc. |
Use of tryptanthrin compounds for immune potentiation
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
US20050215795A1
(en)
*
|
2004-02-06 |
2005-09-29 |
Bang-Chi Chen |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
CA2594713A1
(en)
|
2005-01-26 |
2006-08-03 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine and thymidine phosphorylase inhibitor
|
EA015922B1
(ru)
|
2005-11-14 |
2011-12-30 |
Ариад Фармасьютикалз, Инк. |
ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
|
JO2660B1
(en)
*
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
AU2007228984B2
(en)
|
2006-03-22 |
2012-05-03 |
Syncore Biotechnology Co., Ltd |
Treatment of triple receptor negative breast cancer
|
NZ575274A
(en)
|
2006-08-08 |
2010-11-26 |
Chugai Pharmaceutical Co Ltd |
Pyrimidine derivative as pi3k inhibitor and use thereof
|
US8222288B2
(en)
*
|
2006-08-30 |
2012-07-17 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
EA200901065A1
(ru)
|
2007-02-06 |
2010-02-26 |
Новартис Аг |
Ингибиторы pi 3-киназы и способы их применения
|
WO2009066084A1
(en)
*
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
KR20100103819A
(ko)
*
|
2007-12-13 |
2010-09-28 |
노파르티스 아게 |
암을 치료하기 위한 치료제의 조합물
|
WO2009155659A1
(en)
*
|
2008-06-27 |
2009-12-30 |
The University Of Queensland |
Combination therapy
|
EP2349984A1
(en)
*
|
2008-10-17 |
2011-08-03 |
Merck & Co. |
Combination therapy
|